What is the inheritance risk of a pathogenic sarcomere gene mutation in a patient with hypertrophic cardiomyopathy, and what genetic testing and family screening are recommended?

Inheritance Risk and Genetic Testing in Hypertrophic Cardiomyopathy

Each offspring of a patient with hypertrophic cardiomyopathy who carries a pathogenic sarcomere gene mutation has a 50% chance of inheriting the variant, following autosomal dominant inheritance. 1

Genetic Architecture and Inheritance Pattern

HCM follows autosomal dominant inheritance with incomplete penetrance and variable expressivity 2. This means:

• 50% transmission risk to each child, regardless of sex
• Not all who inherit the mutation will develop clinical disease (incomplete penetrance)
• Among those who do develop HCM, the age of onset and severity varies dramatically—even within the same family with identical mutations 3

The genetic yield varies by clinical context:

• 30-60% of patients with HCM harbor identifiable pathogenic/likely pathogenic variants 1
• Up to 60% yield in familial cases and younger patients with typical asymmetric septal hypertrophy 2
• Only 30% yield in sporadic cases 2
• The remaining 40-70% have no identifiable genetic cause, suggesting other mechanisms 1

Which Genes Matter

The 8 core sarcomere genes account for most genotype-positive cases 1:

• MYH7 and MYBPC3 are the two dominant genes, identified in most variant-positive patients
• Other genes (TNNI3, TNNT2, TPM1, MYL2, MYL3, ACTC1) each account for only 1-5% 1
• Most variants are "private" (unique to individual families) 1

Important caveat: Patients with sarcomere mutations have worse outcomes than genotype-negative patients, including earlier disease onset, higher sudden cardiac death risk, more ventricular arrhythmias, atrial fibrillation, heart failure, and overall mortality 4, 5

Genetic Testing Strategy: The Algorithmic Approach

Step 1: Test the Proband First

Always begin genetic testing with the clinically affected individual (proband) who has clear phenotypic HCM 4. Testing phenotype-negative relatives without a known family mutation has very low yield and is not recommended 4.

Step 2: Interpret the Proband's Result

If pathogenic/likely pathogenic variant identified:

• Proceed to cascade testing in at-risk first-degree relatives 4
• This is the ONLY scenario where family testing is clinically actionable

If no pathogenic variant found (genotype-negative):

• Do NOT test family members 4
• Benign or likely benign variants do not change clinical management
• Family members still require ongoing clinical screening based on phenotype risk alone

If variant of unknown significance (VUS) found:

• This is NOT clinically actionable 4
• Do not use VUS results to guide family screening decisions
• Family members require standard clinical surveillance

Step 3: Cascade Testing in At-Risk Relatives

For relatives of genotype-positive probands:

Genotype-positive relatives (inherited the mutation):

• Require lifelong clinical surveillance with ECG and echocardiography every 1-2 years, even if phenotype-negative 4
• Higher risk for developing HCM over time
• Increased risk of adverse cardiac events compared to genotype-negative relatives (HR 3.3) 6

Genotype-negative relatives (did not inherit the mutation):

• Can be released from further clinical surveillance 4
• No further follow-up required
• This is the major clinical utility of genetic testing—definitively identifying who can stop screening

Critical Pitfall: Variant Reclassification

Variants can be downgraded over time as genetic knowledge expands 4. A variant initially classified as pathogenic may later be reclassified as VUS or benign. When this occurs:

• Relatives previously released from surveillance must be notified immediately
• Clinical screening must be recommenced 4
• This underscores the need for periodic reassessment of variant classification 2

Family Screening Recommendations

For phenotype-negative, genotype-positive relatives:

• Clinical assessment, ECG, and echocardiography every 1-2 years in adults 4
• Every 2-3 years in children 4
• CMR for sudden cardiac death risk assessment if no ICD present 4
• Ambulatory ECG monitoring every 3-5 years 4

The interval may be extended in stable adult patients after multiple evaluations 4.

Prognostic Implications of Genotype Status

Genotype-positive patients demonstrate 6:

• Larger interventricular septal thickness (13.9 mm) compared to genotype-negative individuals (12.3 mm), though less than probands (22.1 mm)
• 4-fold increased risk of major adverse cardiac events compared to genotype-negative relatives
• More frequent ventricular tachycardia (23.4% vs 14.1%), syncope (18.3% vs 10.9%), and heart failure (17.3% vs 14.6%) 5

1, 4, 6, 7, 2, 8, 5